Tilray's Distribution Segment Drives Most of Its Growth in Fiscal 2026
Tilray Brands reported a total net revenue of $915.5 million for fiscal year 2026, representing an 11% increase from the prior year. While all segments showed growth, it was the distribution business that led with a significant 21% rise in revenue to over $327 million. This segment includes pharmaceutical and wellness product sales through international operations like CC Pharma. Despite Tilray's expansion into beverages and cannabis production, its beverage unit only grew by nearly 6%, underperforming expectations for such a strategic focus area. The company remains unprofitable with an operating loss of $63 million during the fiscal year. CEO Irwin Simon highlighted Europe as a key growth region due to their comprehensive medical cannabis distribution platform. Tilray's stock has seen recent gains but is still down nearly 50% from the start of the year, reflecting ongoing investor skepticism about its long-term viability and profitability in the competitive cannabis sector.
Tickers: $TLRY